Abbott Acquires Exact Sciences to Expand Cancer Screening Business
雅培收購 Exact Sciences 以擴展癌症篩檢業務
On March 23, 2026, healthcare giant Abbott Laboratories finalized its acquisition of Exact Sciences for $21 billion.
於2026年3月23日，醫療保健巨頭雅培實驗室（Abbott Laboratories）以210億美元完成了對Exact Sciences的收購。
This strategic deal marks a major expansion into the $60 billion cancer screening and precision oncology diagnostics market.
這筆戰略性交易標誌著其在價值600億美元的癌症篩查和精準腫瘤診斷市場邁出了重要的一步。
By adding Exact Sciences to its portfolio, Abbott aims to build a comprehensive diagnostic ecosystem that covers everything from early detection to monitoring cancer recurrence.
透過將Exact Sciences納入其產品組合，雅培旨在建立一個涵蓋從早期檢測到監測癌症復發（ㄈㄨˋㄈㄚ）的全面診斷生態系統。
Key products included in the merger are Cologuard, a non-invasive colorectal cancer test, and Oncotype DX, a genomic test for personalized breast cancer treatment.
此合併案包含的關鍵產品有：用於非侵入性大腸癌篩檢的Cologuard，以及用於個人化乳癌治療的基因檢測Oncotype DX。
This acquisition reflects a growing trend in the medical technology industry toward platform consolidation, where companies seek to integrate entire technological ecosystems.
此項收購反映了醫療科技產業中，企業尋求整合整個技術生態系統的平台整合趨勢。
For Abbott, the deal also serves as a critical growth lever, helping to diversify revenue streams following the post-pandemic decline in demand for COVID-19 testing.
對雅培而言，這筆交易也是關鍵的成長槓桿，有助於在後疫情時代新冠肺炎檢測需求下降後，實現收入來源的多元化（ㄉㄨㄛㄩㄢˊㄏㄨㄚˋ）。
